Response to Comments: Botulinum Toxins

This document explains that contractor coverage decisions regarding botulinum toxins are based on the best available published clinical evidence and the CMS Program Integrity Manual (CMS Pub. 100-08) Chapter 13, prioritizing peer-reviewed research, systematic reviews, and evidence-based guidelines. Anecdotal or unpublished comments have limited influence; MACs may consolidate or redact stakeholder submissions for proprietary or inappropriate content.

"Anecdotal or unpublished information not subject to peer-review is given limited influence in policy determinations and will not, by itself, change coverage."

Sign up to see full coverage criteria, indications, and limitations.